Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US "Black box" warnings for metoclopramide-containing drugs

This article was originally published in Scrip

Executive Summary

The US FDA has issued a requirement for all metoclopramide-containing medications to add a stronger "black box" warning to their labels about the risk of tardive dyskinesia with chronic use of the drugs.

Advertisement

Related Content

‘Open Science’ In Action: Allergan Exercises Option For Motus After Gastroparesis Study

Topics

Advertisement
UsernamePublicRestriction

Register

SC000547

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel